HRID1587886

反应详情

EQUATION

反应方程式

REACTANTS

反应物

结构：O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+]

HCID13344

Tripotassium citrate

C6H5K3O7

结构：O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[Mg+2]

HCID21986909

未命名化合物

PRODUCTS

生成物

HCID31348

Citrate

C6H5O7-3

结构：O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2]

HCID6099959

Trimagnesium dicitrate

C12H10Mg3O14

HCID21986909

未命名化合物

PROCEDURE

实验过程

Each patient underwent five phases of study: placebo, potassium chloride, potassium citrate, magnesium citrate, and potassium-magnesium citrate. The results (mean values for the two patients) are outlined in Table 1. Compared to potassium chlorlde, potassium magnesium citrate gave a higher urinary pH, magnesium, and citrate. Compared to potassium citrate, potassium magnesium citrate produced a greater citrate excretion as magnesium citrate, potassium magnesium citrate gave higher values for urinary pH and citrate. Finally, compared to the placebo, potassium magnesium citrate produced higher values for urinary pH, magnesium, potassium and citrate, and lower values for urinary calcium and oxalate.

来源与证据

来源类型: Open Reaction Database
ORD 记录: ord-d10562c500f34da6a58ba021cae61824
来源数据集: uspto-grants-1993_06
DOI: 10.6084/m9.figshare.5104873.v1
专利: US05219889
来源说明: uspto-grants-1993_06

反应 SMILES

[C:1]([O-:13])(=[O:12])[CH2:2][C:3]([CH2:8][C:9]([O-:11])=[O:10])([C:5]([O-:7])=[O:6])[OH:4].[K+:14].[K+].[K+].[C:17]([O-:29])(=[O:28])[CH2:18][C:19]([CH2:24][C:25]([O-:27])=[O:26])([C:21]([O-:23])=[O:22])[OH:20].[Mg+2:30].[K+]>>[C:1]([O-:13])(=[O:12])[CH2:2][C:3]([CH2:8][C:9]([O-:11])=[O:10])([C:5]([O-:7])=[O:6])[OH:4].[C:17]([O-:29])(=[O:28])[CH2:18][C:19]([CH2:24][C:25]([O-:27])=[O:26])([C:21]([O-:23])=[O:22])[OH:20].[Mg+2:30].[C:1]([O-:13])(=[O:12])[CH2:2][C:3]([CH2:8][C:9]([O-:11])=[O:10])([C:5]([O-:7])=[O:6])[OH:4].[Mg+2:30].[Mg+2:30].[C:1]([O-:13])(=[O:12])[CH2:2][C:3]([CH2:8][C:9]([O-:11])=[O:10])([C:5]([O-:7])=[O:6])[OH:4].[Mg+2:30].[K+:14]